At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers want to see how well ivosidenib works to treat conventional chondrosarcoma that has metastasized (spread). Chondrosarcoma is a type of bone cancer that forms in cartilage cells. The people in this study have metastatic conventional chondrosarcoma that has a mutation (change) in the IDH1 gene.
-
A Phase 1-2 Study of Nadofaragene Firadenovec in People With Low-Grade Upper Tract Urothelial CancerNadofaragene firadenovec is a gene therapy that delivers a copy of a protein called IFNa2b to your kidney. This may help your immune system find and destroy cancer cells. By killing the cancer cells, nadofaragene firadenovec may cause your cancer to stop growing and spreading.
-
Researchers want to find the highest dose of DISC-0974 to use in people with myelofibrosis and anemia. Myelofibrosis happens when bone marrow cells called fibroblasts make too much fibrous (scar) tissue. The bone marrow is not able to make enough blood cells, which leads to anemia. Anemia is a reduced number of red blood cells, and it causes tiredness and shortness of breath.
-
The purpose of this study is to assess the safety and effectiveness of different combinations of drugs to treat advanced clear cell renal cell carcinoma, a type of kidney cancer, in patients who have not received any prior treatment or who have recently developed worsening disease while receiving immunotherapy that targets the PD-1/PD-L1 proteins.
-
The purpose of this study is to see whether the combination of melphalan, BCNU, vitamin B12b, and vitamin C, followed by autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer who have a BRCA1 and/or BRCA2 gene mutation. All of these treatments are given intravenously (by vein).
-
Researchers want to find the best dose of ZL-1310 to use in people with advanced digestive tumors. The people in this study have gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) that spread and keeps growing after treatment. These tumors include NEC of the esophagus, stomach, pancreas, gallbladder, or colon/rectum.
-
Researchers want to see if combining AZD0901 and rilvegostomig with standard chemotherapy works well in people with gastric or gastroesophageal junction (GEJ) cancer. GEJ cancer occurs where the esophagus joins the stomach.
-
Researchers want to find the best dose of AZD9592 to use in people with lung and head and neck cancers. They will assess AZD9592 when it is given alone and with the anti-cancer drug osimertinib. The people in this study have advanced non-small cell lung cancer (NSCLC) or head and neck cancer with mutations (changes or variants) in the EGFR gene.
- A Phase II Study of Pembrolizumab Immunotherapy plus Chemotherapy followed by Autologous Stem Cell Transplantation for Recurrent or Persistent Hodgkin Lymphoma
Full Title Phase II Study of Second-Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Purpose
The purpose of this study is to assess the safety and effectiveness of combining pembrolizumab immunotherapy with standard chemotherapy drugs and autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma that has come back or continued to grow despite one regimen of prior therapy. Pembrolizumab blocks PD-1, a protein cancer cells use to evade detection by the immune system, thereby enabling the immune system to find and kill cancer cells.
In this study, patients will receive pembrolizumab with three chemotherapy drugs: gemcitabine, vinorelbine, and liposomal doxorubicin. Depending on how well they respond to this treatment, they may also have ASCT. During ASCT, a patient’s own blood-forming stem cells are collected, and he or she is then treated with high doses of chemotherapy. Afterward, the collected stem cells are re-infused back into the patient to re-establish the blood-forming system.
The drugs used in this study are given intravenously (by vein).
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have recurrent or persistent Hodgkin lymphoma after no more than one prior regimen of therapy.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 10 and older.
For more information and to inquire about eligibility for this study, please contact Dr. Alison Moskowitz at 212-639-4839.
Protocol
18-160Phase
Phase II (phase 2)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT03618550ClinicalTrials.gov
-
Doctors are assessing a new photodynamic therapy (PDT) for prostate cancer that has not spread beyond the prostate. This treatment is performed in an operating room while you are under general anesthesia.